The nation's largest pharmacy benefit manager plans to control costs from new cholesterol drugs through discounts and restricting use.» Read More
U.S. biotech shares extended their downward spiral on Tuesday as concerns about drug pricing continued to plague the sector.
CNBC's Bertha Coombs reports on biotech's 6 percent drop on the day.
William Reinsch, president of the National Foreign Trade Council (NFTC), expects Congress to vote on the Trans-Pacific Partnership (TPP) deal in April or May next year.
Spark Therapeutics will apply for U.S. approval of its single treatment for genetic blindness, reports CNBC's Meg Tirrell.
Spark Therapeutics plans to file for U.S. regulatory approval next year for the first gene therapy product on the market in the U.S.
CNBC's Meg Tirrell reports Spark Therapeutics will apply for U.S. approval of its single treatment for genetic blindness.
Savita Subramanian, head of U.S. equity and quantitative strategy, BofA Merrill Lynch, says the S&P 500 is the most "liquid play on generally high quality companies."
Novocure shares tumble in Nasdaq debut
Morgan Stanley analyzed the drug pricing issue and found which companies are the best and worst positioned in a note sent to clients on Thursday.
The real problem with biotech has to do with the size of biotech firms, says industry CEO Robert Mulroy. Here's why.
Michael Thompson, managing director for Global Markets Intelligence at S&P Capital IQ, says there is still scope to replace labour with capital through technological advances, especially in industries such as healthcare.
Neera Tandan, Center for American Progress president, weighs in on the best ways to control prices in the prescription drug market and encourage company's to put money into research and development rather than marketing.
David Amsellem, senior research analyst at Piper Jaffray, discusses news that U.S. Democratic lawmakers denounced Valeant Pharmaceuticals for increasing the prices of two heart drugs.
David Kudla, CEO & chief investment strategist at Mainstay Capital Management, says Wall Street is still seeing a correction amid an ongoing secular bull market.
With the IBB performing poorly and increased confusion in the biotech market, is it time for investors to be bullish?
CNBC's Bertha Coombs highlights the rebound in biotech after suffering one of the sector's worst day in years.
From Steve Cohen and the SEC to Sage Kelly's divorce, here are five epic Wall Street fights — and how they played out.
Jeff Jonas, Gabelli Funds, weighs in on the biotech's political backdrop as the space experienced a rough week.
CNBC's Meg Tirrell takes a look at what's prompting the sell-off in biotech stocks.
Biotech stocks took a dive Monday, and some CNBC "Fast Money" traders say the struggles could extend to other high-growth names.
Get the best of CNBC in your inbox